TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, revealing differences between TD patients with a psychotic disorder and those with a mood disorder. The IMPACT-TD Registry is the largest study of its kind evaluating the holistic effects of TD, showing real-world treatment patterns and outcomes with once-daily AUSTEDO® XR® (deutetrabenazine) extended-release tablets and twice-daily AUSTEDO (deutetrabenazine) tablets. Teva also announced interim data from a patient-reported survey describing early, real-world experience with AUSTEDO XR. These findings are being presented at the Psych Congress 2024 taking place from October 29 – November 2 in Boston, MA.
“Tardive dyskinesia is underdiagnosed and often little-understood while presenting a major negative impact on all aspects of a patient’s life. Our latest research is part of Teva’s efforts to build better outcomes, as we seek to improve the day-to-day lives of the patients we serve,” said Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer at Teva. “As we continue driving meaningful innovation and lead efforts to tackle mental health equity gaps in care, we are steadfastly committed to understanding the experience of those who are living with TD and look forward to additional insights as we continue this registry.”
The two-part IMPACT-TD study is a three-year longitudinal observational study evaluating how TD progresses and impacts a patient’s quality of life, as well as outcomes related to treatment with once-daily AUSTEDO XR and twice-daily AUSTEDO. The study includes adult patients identified to have TD, but a formal TD diagnosis was not required to participate.
The IMPACT-TD findings revealed:
“It is critical for people with psychotic disorders to get the treatment that they need. In the past several years, antipsychotic medicines use has increased, leading to an increased risk of developing TD,” said Rakesh Jain, MD, MPH, Clinical Professor of Psychiatry, Texas Tech University School of Medicine – Permian Basin. “Taken together, the results of this physician- and patient-reported data reveal the need to more closely monitor patients suffering from mental health conditions for signs of TD so that they can be treated early and effectively.”
Teva also presented findings on real-world patient experience with AUSTEDO XR from a non-interventional, prospective, cross-sectional survey, which included adults with TD or Huntington’s disease (HD) chorea who were prescribed the medication. The survey explored patient-reported ease of use, effectiveness and satisfaction. In this interim analysis of data from 131 respondents:
Currently more than 57 million Americans are living with a mental illness, 14 million of whom are living with a serious mental health condition.1 For those taking certain mental health medications, one in four may experience the onset of TD, an often-overlooked chronic movement disorder that can have a physical, emotional and psychological impact on patients.2,3 Both TD and HD chorea can pose significant challenges to patients’ every day lives as simple tasks like eating, talking and walking can be impacted.
For full release, please visit:
https://www.globenewswire.com/en/news-release/2024/11/01/2973521/0/en/Teva-Presents-New-Tardive-Dyskinesia-Data-at-Psych-Congress-2024-from-the-IMPACT-TD-Registry-Revealing-Differences-in-Patient-Experience-Based-on-Underlying-Psychiatric-Condition.html